secwatch.observer — SEC 8-K summary
======================================

Issuer:     OPKO HEALTH, INC. (OPK)
CIK:        0000944809
Form:       8-K
Filed at:   2025-09-15T23:59:59+00:00
Accession:  0001193125-25-203530
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OPKO completes sale of BioReference oncology assets to Labcorp for $192.5M cash plus earnout
--------------------------------------------------------------------------------

- Transaction closed Sept 15, 2025; Labcorp paid $192.5M at closing, with up to $32.5M earnout.
- Assets include BioReference's oncology and oncology-related clinical testing services across the U.S.
- OPKO to use portion of proceeds for share repurchase; continuing ops had ~$300M revenue in 2024.
- CEO Phillip Frost says deal positions BioReference to focus on core testing and 4Kscore franchise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/944809/000119312525203530/0001193125-25-203530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/944809/000119312525203530/opk-20250915.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-203530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer